72
Participants
Start Date
February 9, 2022
Primary Completion Date
June 30, 2026
Study Completion Date
December 31, 2027
Association of berzosertib with gemcitabine
"Gemcitabine will be administered by intravenous 30-minutes infusion on days 1 and 8 every 3 weeks, at a fixed dose of 1000 mg/m².~Berzosertib will be administered intravenously on days 2 and 9 every 3 weeks (210 mg/m²).~A treatment cycle consists of 3 weeks (i.e., 21 days) and will be administered during hospitalization."
Gemcitabine
"Gemcitabine will be administered by intravenous 30-minutes infusion on days 1 and 8 every 3 weeks, at a fixed dose of 1000 mg/m².~A treatment cycle consists of 3 weeks (i.e., 21 days) and will be administered during hospitalization."
RECRUITING
IUCT Oncopôle, Toulouse
RECRUITING
Institut Bergonié, Bordeaux
WITHDRAWN
Institut de Cancérologie de l'Ouest, Saint-Herblain
RECRUITING
Centre Leon Berard, Lyon
RECRUITING
CHU Poitiers, Poitiers
RECRUITING
Institut Gustave Roussy, Villejuif
Lead Sponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
INDUSTRY
Institut Bergonié
OTHER